Biomarin Pharmaceutical Inc’s recently made public that its EVP, Chief Technical Officer Guyer Charles Greg unloaded Company’s shares for reported $0.5 million on Mar 06 ’25. In the deal valued at $71.28 per share,7,034 shares were sold. As a result of this transaction, Guyer Charles Greg now holds 87,655 shares worth roughly $6.27 million.
Then, Guyer Charles Greg bought 7,034 shares, generating $501,359 in total proceeds.
Before that, Burkhart Erin sold 1,344 shares. Biomarin Pharmaceutical Inc shares valued at $91,903 were divested by the GVP, Chief Accounting Officer at a price of $68.38 per share. As a result of the transaction, Burkhart Erin now holds 13,105 shares, worth roughly $0.94 million.
Oppenheimer upgraded its Biomarin Pharmaceutical Inc [BMRN] rating to an Outperform from a a Perform in a research note published recently. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid November with a ‘”an Outperform”‘ rating. William Blair also remained covering BMRN and has decreased its forecast on October 30, 2024 with a “Mkt perform” recommendation from previously “an Outperform” rating.
Price Performance Review of BMRN
On Tuesday, Biomarin Pharmaceutical Inc [NASDAQ:BMRN] saw its stock fall -0.04% to $71.52. Over the last five days, the stock has gained 1.46%. Biomarin Pharmaceutical Inc shares have risen nearly 8.81% since the year began. Nevertheless, the stocks have fallen -15.25% over the past one year. While a 52-week high of $94.85 was reached on 03/07/25, a 52-week low of $60.63 was recorded on 01/16/25. SMA at 50 days reached $66.52, while 200 days put it at $73.77.
Levels Of Support And Resistance For BMRN Stock
The 24-hour chart illustrates a support level at 70.84, which if violated will result in even more drops to 70.16. On the upside, there is a resistance level at 72.19. A further resistance level may holdings at 72.86. The Relative Strength Index (RSI) on the 14-day chart is 61.07, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.06, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 39.10%. Stochastics %K at 47.48% indicates the stock is a holding.
How much short interest is there in Biomarin Pharmaceutical Inc?
A steep rise in short interest was recorded in Biomarin Pharmaceutical Inc stocks on 2025-02-28, dropping by -0.27 million shares to a total of 4.24 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 4.5 million shares. There was a decline of -6.27%, which implies that there is a negative sentiment for the stock.
